Drug Type Small molecule drug |
Synonyms Temuterkib Mesylate, LY 3214996 |
Target |
Mechanism ERK1 inhibitors(Extracellular-signal-regulated kinase1 inhibitors), ERK2 inhibitors(Extracellular-signal-regulated kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H27N7O2S |
InChIKeyJNPRPMBJODOFEC-UHFFFAOYSA-N |
CAS Registry1951483-29-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | US | 05 Oct 2020 | |
Advanced cancer | Phase 2 | US | 27 May 2020 | |
Secondary malignant neoplasm of pancreas | Phase 2 | US | 27 May 2020 | |
KRAS mutant Colorectal Cancer | Phase 1 | NL | 31 Mar 2022 | |
KRAS mutation-related tumors | Phase 1 | NL | 31 Mar 2022 | |
Non-Small Cell Lung Cancer | Phase 1 | NL | 31 Mar 2022 | |
Pancreatic Ductal Adenocarcinoma | Phase 1 | NL | 31 Mar 2022 | |
Acute Myeloid Leukemia | Phase 1 | US | 15 Jul 2020 | |
Recurrent Glioblastoma | Phase 1 | US | 08 Jul 2020 | |
Colorectal Cancer | Phase 1 | US | 29 Sep 2016 |
NCT04534283 (ASCO2023) Manual | Phase 2 | 12 | jganktjytz(jyadjohkth) = pkrzkvtffv hjcfqsqsfd (vmksztyqdy ) View more | Positive | 31 May 2023 | ||
NCT02857270 (ASCO2019) Manual | Phase 1 | 51 | rnmyruijxx(avslwvwlzx) = grade (G) 3 cough and fatigue, G3 dehydration, increased creatinine (Cr), G3 increased CPK, G3 rash > 7 days, and 1 pt with renal failure. aweozsqlbe (ckulfedrgr ) View more | Positive | 03 Jun 2019 | ||
Phase 1 | - | 210 | kigpntwxnx(cjlgxnnehg) = gqmfveydmu ylkztytlvr (cuxdbzxkic ) | - | 01 Jul 2017 | ||
Phase 1 | 210 | ccvggqmbqi(hmpuxvzgon) = ggngsyfodq ifijqmpzay (pyfcrggyan ) | Positive | 01 Jul 2017 |